Intestinal immunopathology was studied after allogeneic stem cell transplantation (SCT) in a common clinical setup in 20 children with malignant (n ¼ 17) or nonmalignant diseases (n ¼ 3) receiving grafts from siblings (7) and unrelated donors (13). In all, 19 had total body irradiation. Duodenal biopsies at 6 and 12 weeks post transplant were evaluated by histology, immunohistochemistry, and ISEL for the detection of T-lymphocytes, inflammatory cytokines, proliferation, and apoptosis. The controls were 12 healthy children and three patients with proven intestinal graft-versus-host disease. An increased rate of apoptosis and proliferation with upregulated expression of HLA-DR antigen was detected up to 3 months post transplant in the SCT patients, even in those with a histologically normal small intestine. A low level of IFNc and TNFa was observed in the lamina propria. The initial low density of cd-positive T cells had recovered to normal by the time of the second endoscopy at 12 weeks post transplant. We conclude that inflammatory activity and T cell infiltration detected by immunohistochemistry may not belong to the 'normal' recovery of the small intestine after SCT. Increased cell turnover in the intestinal crypts continues until 3 months after SCT, suggesting either an unexpectedly long-lasting effect of transplant-related toxicity or, preferably, an ongoing subclinical alloreactive process, also present in the patients without intestinal symptoms.
tine; stem cell transplantation Gastrointestinal symptoms are common in patients undergoing allogeneic stem cell transplantation (SCT). Up to one-half of SCT patients have been reported to have gastrointestinal symptoms severe enough to warrant evaluation by endoscopy. 1 Approximately 10-50% of patients with a sibling donor 2, 3 and 68% of those with a matched, unrelated donor (URD) 3 develop acute graft-versus-host disease (GVHD). The gastrointestinal tract is one of the principal target organs of GVHD. In experimental models, the histology of acute intestinal GVHD advances from early proliferation to destruction, and finally to atrophy of the mucosa and loss of mucosa-associated lymphocytes, 4 with single-cell necrosis being the hallmark of GVHD. [5] [6] [7] In the clinical setting, the histological diagnosis of intestinal GVHD is, however, complicated by several factors, including destructive changes caused by the conditioning regimen, and by viral infections. The histology of intestinal irradiation damage resembles that of GVHD in revealing apoptotic cells, loss of lymphocytes and, in advanced cases, villous atrophy and scarring of the mucosa. 8 In addition, primary or secondary CMV infection is often present in the intestine of immunocompromised patients. 9 Little is known about the 'normal' course of intestinal histology during the early phases after SCT.
The aim of our study was to evaluate prospectively the histology of the small and large intestine, as well as the immunohistochemical features of the duodenum, in a standard clinical setting after allogeneic SCT.
Patients and methods

Patients
This prospective study was run at the Hospital for Children and Adolescents, University of Helsinki, Finland, between November 1995 and October 1998. Initially, 44 consecutive patients aged over 1 year were invited prior to allogeneic SCT, and 20, 14 males and six females, aged 1-13 years, were willing to take part. The diagnoses were ALL (n ¼ 10), AML (n ¼ 4), X-linked lymphoproliferative disease (n ¼ 1), juvenile chronic myeloid leukemia (n ¼ 1), monosomy 7 (n ¼ 1), Hunter's disease (n ¼ 1), adrenoleukodystrophy (n ¼ 1), and severe aplastic anemia (n ¼ 1). The conditioning regimen consisted of total body irradiation (TBI) of 10/ 12/14 Gy (13/4/2 patients) together with cytarabine, cyclophosphamide, or melphalan. One patient received total nodal irradiation of 8 Gy with busulfan and cyclophosphamide. The donors were seven HLA-matched siblings and 13 unrelated donors either from the Finnish National Bone Marrow Donor Registry or from international registries. All donors except one URD (5/6 match) were 6/6 HLA-matched with the recipients. The SCT patients who did not take part in the study did not differ from the study population with respect to demographic or clinical characteristics. The study protocol was approved by the Institutional Review Board. Oral witnessed informed consent was obtained from the parents and age-appropriate patients.
The symptoms recorded were the maximal volume of diarrhea (ml/kg/day), fever (days with fever X38.01C during the first post transplant month), semiquantitative estimates of post transplant vomiting (grades 1-3; 1 ¼ irregularly, not every day; 2 ¼ every day, less than three times per day; and 3 ¼ every day, more than three times per day), and abdominal pain (1 ¼ irregularly, not every day; 2 ¼ every day, occasional pain killers needed; and 3 ¼ every day, regular pain killers needed) occurring after engraftment up to 6 weeks. Stools and nasopharyngeal secretions were cultured for bacteria, fungi, and viruses once a week. CMV viremia was checked weekly with an early antigen test.
All patients received cyclosporine from day À1 and methotrexate on days 1, 3, 6, and 11, as conventional GVHD prophylaxis. The signs and symptoms of GVHD were recorded and graded according to the conventional criteria. 10 
Controls
Controls with severe intestinal GVHD. Three SCT patients with grade 3-4 clinical and histologically proven gastrointestinal GVHD served as controls. Conditioning regimen (either melphalan, cytarabine, or cyclophosphamide with 12 Gy TBI), donors (one HLA-matched sibling, two matched URDs), median dose of nucleated cells in the stem cell graft, and GVHD prophylaxis given were similar to the study patients.
Healthy controls. The healthy controls were 12 children (median age 6.7, range 1.6-13.7 years) who underwent esophagogastroduodenoscopy (OGD scopy) due to abdominal discomfort and/or growth delay, and whose duodenal histology was normal. Of these, 10 of them had positive antigliadin antibodies, including IgA antibodies in three and IgG antibodies in 10, but none of them had positive tissue transglutaminase or endomysium antibodies.
Endoscopic procedures
OGD scopy and colonoscopy were prospectively scheduled at 6-7 and 12 weeks after SCT. The first endoscopy at 6 weeks was performed in 17/20 study patients. Two patients with intestinal symptoms were excluded not in a sufficiently good condition for anesthesia, and one patient refused endoscopy. Follow-up endoscopy at 12 weeks was performed in 12 patients. There were eight dropouts; one had relapse of ALL, four refused endoscopy, and three had died. None was on corticosteroid treatment at the time of the first endoscopy, while three had steroids at week 12. The three GVHD controls underwent endoscopies at the time of early but obvious intestinal symptoms at 3, 6, and 11 weeks, respectively. All endoscopies were performed under general anesthesia. A Watson biopsy device or a gastroscope was used to take specimens from the distal duodenum or the proximal jejunum of the healthy controls.
Biopsy specimens
Biopsy specimens were taken from the gastric mucosa, the distal duodenum, and sigma for routine histology, and from the distal duodenum for immunohistochemistry. The intestinal biopsy samples were stained routinely by hematoxylin and eosin and analyzed by one pathologist (RK) blinded for the clinical data. The histological grading of intestinal GVHD ranged from signs of apoptosis and infiltration of intraepithelial lymphocytes (grade 1) through exploding crypts (grade 2) and loss of crypts (grade 3) to total sloughing off of the epithelium (grade 4). The biopsy sample from the duodenum for immunohistochemistry was embedded in optimal cutting temperature compound (Miles Laboratories, Elkhart, IN, USA), snap-frozen in liquid nitrogen, and stored at À701C until analysis. Frozen tissue samples were cut into 8-mm sections for immunohistochemistry and in situ end labelling (ISEL). The sections were coded and evaluated without knowledge of the clinical data.
Immunohistochemistry
The avidin-biotin immunoperoxidase system was used on native cryostat sections as described previously. 11 Prior to incubation with monoclonal antibodies (mAbs) against cytokines, permeabilization was performed by incubation of the slides in 0.1% PBS-Tween-20 for 10 min at room temperature, diluted in 1% normal horse serum in 0.1% PBS-Tween-20 for 1 h at þ 371C.
The following mAbs were used at the following dilutions: CD3 
Microscopical evaluation of immunohistochemistry
Numbers of positively stained cells were counted under a light microscope through a calibrated graticule at Â 1000 magnification, as described previously. 12 In the same specimen, the positive cells in at least 30 fields either along the epithelium or comprising the lamina propria were counted, and cell densities were expressed as cells/mm or cells/mm 2 , respectively. The microscopic evaluation was performed independently by two investigators (MWO and GV).
Epithelial staining with HLA-DR and HLA-DP was graded from 2 to 6 according to the intensity and cellular distribution (1-3) and area of staining (1-3). 13 The proportion of the lamina propria that stained positively for ICAM-1 was estimated and graded from 1 to 3 according to the intensity of staining, 1 representing faint and 3 strong staining. Ki-67-positive cells were calculated as the percentage of the crypt cells, with at least 200 crypt cells counted in each specimen.
ISEL of DNA fragmentation
DNA fragmentation was identified by using the in situ DNA 3 0 -end labelling method as described previously.
14 Cryostat sections (8 mm) were fixed in acetone and incubated with 0.3% H 2 O 2 to eliminate endogenous peroxidase activity. After incubation for 10 min with terminal transferase reaction buffer containing 1 mM CoCl 2 (Roche Diagnostics, Mannheim, Germany), the apoptotic DNA fragments were 3 0 -end labelled with digoxigenin-11-ddUTP (0.5mM, Roche Diagnostics) by terminal transferase reaction (TdT enzyme 375 U/ml, Roche Diagnostics) at 371C for 1 h. Following blocking of nonspecific binding with 2% blocking reagent, the sections were incubated with horseradish peroxidase-conjugated antidigoxigenin antibody (1:200, Roche Diagnostics). The color was developed with diaminobenzidine (Sigma, St Louis, MO, USA) and light counterstaining was performed with hematoxylin. For negative controls, the TdT enzyme or labelled nucleotides were replaced by distilled water, and for positive controls the sections were incubated with DNAse (1 or 10 IU/ml, Promega, Madison, WI, USA) at 371C for 15 min prior to the TdT reaction. Patient sections were always processed in parallel with controls and a total of three sections per patient were analyzed. The number of enterocytes with DNA fragmentation was calculated as percentages of positive epithelium cells along the surface epithelium and in the crypt epithelium, with at least 200 cells counted in each compartment, and always counting the entire villus.
Statistical analyses
SPSS software (SPSS Inc., Chicago, IL, USA) was used in statistical analyses. The nonparametric test of KruskalWallis was used to analyze the association between histological and clinical grade of GVHD, and immunohistochemical parameters between the groups. The MannWhitney U-test was used to analyze immunohistochemical parameters of the study patients vs the controls, as well as to analyze the difference between the first and second endoscopy findings. The correlation between proliferation and apoptosis markers in the SCT patients was analyzed with Spearman's correlation.
Results
Histology
The endoscopy at 6 weeks was performed in 17/20 patients. The histology, together with clinical symptoms, is presented in Table 1 . All four with severe nausea and vomiting had normal histology in the duodenum, as well as in the gastric mucosa. Histological findings were more common in the large than in the small intestine. GVHD, limited to grade 1 and 2, was diagnosed histologically in the large intestine in four patients, two of whom had vomiting and mild diarrhea that had already started right after the conditioning (Table 1) .
Follow-up endoscopy at 12 weeks was performed in 12/ 16 patients (Table 1) . Four patients had clinical intestinal symptoms at the time of the second endoscopy, three having vomiting only. The small intestine was histologically normal in all except for the patient with diarrhea. Histologically, the large intestine revealed GVHD in five patients (one grade 1, three grade 2 and one grade 4). In addition, histological changes of GVHD, all present in the large intestine, were found in 4/13 (the first endoscopy) and in 2/8 (the second endoscopy) patients without gastrointestinal symptoms starting at engrafting or later. Taken together, none of the patients with vomiting had histological evidence of GVHD in the gastric mucosa or in the duodenum either at the first or second endoscopy. Histological GVHD was common in the large intestine in patients without gastrointestinal symptoms fitting clinically with GVHD.
Viral cultures from the stools and CMV early antigen detection from biopsy material and blood were negative. Surveillance cultures revealed enterococci, Klebsiella, and Escherichia, but yeasts Pseudomonas, Clostridium, or staphylococci were not detected.
Immunohistochemistry and ISEL at 6 weeks
The SCT patients had significantly lower levels of abpositive lymphocytes intraepithelially and gd-positive lymphocytes in the lamina propria than the healthy controls ( Figure 1 ). The level of CD3-positive T cells was comparable between SCT patients and healthy controls.
Staining of HLA-DR molecules in the intestine was stronger in the SCT patients (median 5, range 2-6) than in the healthy controls (median 2, range 2-6) (P ¼ 0.006). Expression of HLA-DP and the adhesion molecule ICAM-1 did not differ between the SCT patients and healthy controls.
The SCT patients had significantly higher median levels of IL-1a at 6 weeks and lower median levels of TNFa in the small intestine than did the healthy controls (Figure 2 ). The 
Histology of duodenal and sigmoid mucosa in individual 20 patients at 6 and 12 weeks after SCT is presented in relation to the leading gastrointestinal symptom, that is, vomiting vs diarrhea. GVHD ¼ graft-versus-host disease; ND ¼ not defined; gr ¼ grade; w ¼ dead; * ¼ refused.
Intestinal mucosa after SCT
M Taskinen et al median density of IFNg-positive cells in the epithelial compartment, but not in the lamina propria, was higher in the SCT patients than in healthy controls (Figures 1a  and 2) . A high level of cell turnover was observed in the SCT patients as opposed to the healthy controls. The percentage of crypt cells positive for Ki-67 (a proliferation marker) was significantly higher in the SCT patients than in the healthy controls (Figures 3 and 4a) . The percentage of apoptotic cells in the epithelium and in crypts was higher in the SCT patients than in healthy controls. The rate of proliferation (Ki-67 crypts) and apoptosis (ISEL crypts) correlated significantly (Figure 4b ) (r ¼ 0.40, P ¼ 0.01, Spearman's correlation).
Immunology in the first vs the second endoscopy
By the time of the second endoscopy, the median density of lamina propria gd T cells had increased from 22.1 (range 13.6-58.6) to 42.5 (range 21.6-141.1) positive cells/mm 2 (P ¼ 0.017), as compared to the first endoscopy in the SCT patients. The other parameters did not differ between the first and second endoscopy (Figure 1) .
Compared to the healthy controls, the second biopsy of SCT study patients showed the same tendencies as the first biopsy with regard to lower densities of abTCR-positive intraepithelial lymphocytes and TNFa-positive cells in the lamina propria, and higher densities of IFNg-positive intraepithelial cells and IL-1a-positive cells in the lamina propria. The expression of HLA-DR was still increased in the biopsy samples taken 12 weeks post transplant (P ¼ 0.019 when compared to healthy controls). In addition, the density of IL-4-positive cells was significantly higher and the density of IFNg-positive cells was lower in the lamina propria of the second biopsy when compared to healthy controls (Figures 1 and 2 ). The percentage of proliferative and apoptotic epithelial cells were also higher in the second biopsy of SCT patients than in healthy controls (Figure 4a ).
Intestinal immunology and GVHD
Control GHVD patients had slightly higher levels of gdlymphocytes both intraepithelially and in the lamina Figure 1 Densities of duodenal lymphocytes intraepithelially and in the lamina propria. (a) Densities of CD3-, gdTCR-, abTCR-, and IFNgpositive cells in the epithelial compartment detected by immunohistochemistry in duodenal specimens of healthy controls (Co), SCT study patients at 6 (6 wk) and 12 weeks (12 wk) post transplant, and GVHD controls (GVHD). The box plots indicate the median, 25th and 75th percentiles, and the total range. The asterisks indicate significant differences (*Po0.05, **Po0.01, ***Po0.001 when compared to healthy controls, and
Po0.05 when compared to SCT at 6 weeks). (b) Densities of CD3-, gdTCR-, and abTCR-positive cells in the lamina propria detected by immunohistochemistry in duodenal specimens of healthy controls (Co), SCT study patients at 6 weeks (6 wk) and 12 weeks (12 wk) post transplant, and GVHD controls (GVHD). The box plots indicate the median, 25th and 75th percentiles, and the total range. The asterisks indicate significant differences (*Po0.05, **Po0.01, ***Po0.001 when compared to healthy controls, and Po0.05, Po0.01 when compared to SCT at 6 weeks).
Positive cells / mm 2 lamina propria propria than did the SCT patients in the study group (Figure 1) . GVHD controls did not differ from the study group SCT patients with respect to any other investigated parameter. However, compared to the healthy controls, GVHD controls had significantly higher densities of IFNg-positive cells intraepithelially (P ¼ 0.044) ( Figure 1a ) and lower densities of IL-2-positive cells (P ¼ 0.022) in the lamina propria (Figure 2 ). The percentage of apoptotic cells in the epithelium (P ¼ 0.022) and crypts (P ¼ 0.044) was also higher in GVHD controls than in healthy controls (Figure 4a ). In addition, expression of HLA-DP was higher in GVHD controls (median 6, range 4-6, P ¼ 0.048) than in healthy controls (median 3, range 2-5).
Discussion
Following allogeneic SCT in children, we observed a highly increased rate of proliferation and apoptosis in the distal duodenum but no signs of inflammation in prospectively scheduled intestinal endoscopies at 6 and 12 weeks post transplant. In addition, loss of mucosal lymphocytes was obvious. All these findings were also present in patients without symptomatic clinical or histological GVHD.
Histology of the distal duodenum and large intestine was normal in the majority of our patients at 6 and 12 weeks after a common myeloablative regimen and allogeneic SCT. However, immunohistochemical approach revealed active proliferation and apoptosis in the duodenal mucosa. As observed in several studies, proliferation of new enterocytes from the crypts of Lieberku¨hn between the villi increases dramatically after any epithelial damage, including celiac disease, 15 GVHD 5 and irradiation. 8 The strong proliferative capacity of the intestinal mucosa in SCT patients was shown in a prospective study, revealing repair of postirradiation degenerative damages in rectal biopsies by day 20 post transplant in patients without clinical signs of GVHD. 16 The healing process after cytotoxic conditioning regimen may continue far beyond the sensitivity of routine histological methods, and this process might have been detected by immunohistochemistry in our patients. However, the persistence of apoptotic and proliferative activity even as late as at 12 weeks might also suggest an ongoing process, such as infection or GVHD. No evidence of intestinal infection was detected 
Percentage of ISEL Positive crypt cells
Percentage of Positive epithelial cells in frequent sampling for bacteria, yeasts, and viruses in the stools, or in the detection of CMV in the blood and in the biopsy material. Neither was histological GVHD diagnosed in the small intestine in this prospective group. In experimental models, the early stages of intestinal GVHD are characterized by crypt cell proliferation and apoptotic cells. 4, 5 In this study, the histological grading of GVHD was based on epithelial and glandular destruction, and histological signs of proliferation were not classified as GVHD. It is not clear whether the increased cell turnover truly represents an early stage of intestinal GVHD in humans similar to animal models. Immunohistochemistry could be used to demonstrate this increased cell turnover.
The classical signs of intestinal GVHD, vomiting, and diarrhea turned out to be unreliable in our study patients. None with vomiting had histological GVHD documented in biopsies taken at the OGD scopy. In contrast, GVHD histology in the sigma was most often seen in patients without symptomatic clinical GVHD. The accuracy in recalling and recording symptoms always constitutes a potential source of error. However, for the vast majority of our patients, continuous stay in hospital until the first endoscopy should confirm recognition of any symptoms of GVHD. Although histology is considered to be a cornerstone in the diagnosis of gut GVHD, it might be of lower sensitivity, although with high specificity. Also, sampling error is possible. Our results emphasize that diagnosis of intestinal GVHD and potential intensification of immunosuppressive medication should preferably be based on endoscopy and gut histology rather than symptoms only, especially in patients with vague and mild intestinal complaints, such as vomiting. Furthermore, the whole clinical picture of GVHD, including the skin and liver, should be taken into account.
Our results are in accord with Sviland et al, 17 who have described upregulation of HLA-DR in the enterocytes and keratinocytes after allogeneic SCT. Furthermore, increased epithelial HLA-DR expression seemed to last until at least 12 weeks after SCT and was also present in patients without histological characteristics of GVHD. The expression of HLA-DR in the epithelium did not display GVHD activity, most likely due to the very small number of patients in the GVHD control group. Along with the expression of the class II HLA molecules, cytokines, such as IFNg, IL1a, and TNFa, are needed for the development of GVHD. 4, 18 In our patients, the densities of IFNgpositive cells in the intraepithelial compartment and IL1a-positive cells in the lamina propria, but not the expression of TNFa, were increased in the SCT patients as compared to the healthy controls (Figure 2 ). It was surprising that the levels of inflammatory cytokines, IFNg and TNFa, were much lower in SCT patients than, for example, in patients with celiac disease. 19 Considering the development of GVHD, IL1a appears to be the only cytokine to produce recruitment of intraepithelial lymphocytes during the progress of intestinal GVHD. 4 The production of IFNg seems to be essential for evolution of the early, proliferative stages, and TNFa for the more advanced and destructive stages of GVHD. 5, 20 The increased proliferative activity and normal intestinal histology fit with the increased level of intraepithelial IFNg and normal TNFa in our patients. Consequently, while signs of inflammation during the early post transplant period do not necessarily belong to the 'normal' sequence of events, inflammatory activity in the bowel would rather represent a pathological process. More patients with longitudinal follow-up of advanced stages of intestinal GVHD are needed to test the value of ISEL and immunohistochemistry, including Ki-67, IFNg, and TNFa, as tools for early diagnosis and staging of intestinal GVHD.
The level of gd-positive lymphocytes in the lamina propria was reduced at 6 weeks, having reached the levels of the healthy controls by 12 weeks. The decrease of Tlymphocytes, also detected after autologous SCT, 21 probably reflects the effect of the conditioning regimen upon the mucosa. Functionally, intraepithelial gd cells have a major role in the maintenance of the intestinal epithelium and in tissue repair, 22 and can produce a multiplicity of cytokines, including IL-2, IFNg, TNFa, IL10, and TGF-b. 23 The loss of gd cells in SCT patients arouses concern about the adequacy of reparative functions of the intestine and about the maintenance of epithelial integrity. This may render the intestinal epithelium vulnerable to further damage, for example, during viral infections.
Our study has several potential biases, including the limited number of patients undergoing endoscopy. The study setting was prospective with regard to the endoscopy schedule, but only one-half of the patients transplanted during the study period agreed to participate. However, the patients outside the study group did not differ from the patients on-study, and thus patients in the prospective study group are considered representative. The potential errors arising from the immunohistochemical techniques per se include possible differences among the mAbs in different patches, and the technical difficulty in processing biopsy specimens with an advanced destructive process, such as GVHD.
We conclude that in pediatric recipients of allogeneic stem cell grafts, an increased cell turnover in the intestinal crypts continues until at least 3 months post transplant, suggesting either an unexpectedly long-lasting transplantrelated toxicity, or an ongoing subclinical alloreactive process, also present in patients with no intestinal symptoms. The level of T-cell presentation and inflammatory activity in the intestine were low. Immunohistochemistry and the ISEL method might, in combination with histology, be helpful in the evaluation of intestinal pathology of SCT patients.
